Tisotumab vedotin

< 951

Market share is generally not included unless otherwise stated.

150,927,504.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.